# Efficacy of SLITone in House Dust Mite Allergic Patients

> **NCT00633919** · PHASE2,PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 124 (actual)

## Conditions studied

- Allergy

## Interventions

- **BIOLOGICAL:** SLITone(TM) Dermatophagoides mix
- **BIOLOGICAL:** Placebo
- **DRUG:** Salbutamol inhaler
- **DRUG:** Budesonide/formoterol inhaler
- **DRUG:** Prednisone tablet
- **DRUG:** Desloratadine tablet
- **DRUG:** Budesonide nasal spray

## Key facts

- **NCT ID:** NCT00633919
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-12
- **Final completion:** 2009-02
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633919, "Efficacy of SLITone in House Dust Mite Allergic Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00633919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*